Latest Ototoxicity Stories

SEATTLE, Nov. 28, 2012 /PRNewswire/ -- Sound Pharmaceuticals, Inc. is honored to have Bruce A. Beutler, a recipient of the 2011 Nobel Prize in Physiology or Medicine for his discoveries involving the activation of innate immunity, join the company as a scientific advisor. Dr. Beutler is currently the Director of the Center for the Genetics of Host Defense at the University of Texas Southwestern Medical Center. In addition, he has identified and characterized COMT2, a genetic...

Apramycin, already used in animals, shows promise against drug-resistant TB and other 'superbugs,' without hearing loss The world needs new antibiotics to overcome the ever increasing resistance of disease-causing bacteria – but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that kill even "superbugs" but spare the delicate sensory cells of...

Apramycin, already used in animals, shows promise against drug-resistant TB and other "superbugs", without hearing loss ANN ARBOR, Mich., June 11, 2012 /PRNewswire-USNewswire/ -- The world needs new antibiotics to overcome the ever-increasing resistance of disease-causing bacteria - but it doesn't need the side effect that comes with some of the most powerful ones now available: hearing loss. Today, researchers report they have developed a new approach to designing antibiotics that...

Study 'intensely personal' for OHSU researcher, whose deafness was caused by antibiotics Peter Steyger's research on hearing is very personal. That's because Steyger — a research scientist with the Oregon Hearing Research Center at Oregon Health & Science University — is deaf. Now Steyger has published groundbreaking research that is as personal as it gets. The study gives scientists new insight into why a specific class of antibiotics causes deafness — the same class of...

(Ivanhoe Newswire)-- Indulge yourself with folate now, before you deal with the effects later. Studies suggest that age-related hearing loss (ARHL), one of the four most prevalent chronic conditions in the elderly, is associated with low serum levels of folic acid.Hearing loss is a major public health problem globally, with more than 28 million Americans between the ages of 60 and 74 dealing with the loss. Despite the high prevalence of hearing impairment, the biological basis of age-related...

Long-term survivors of testicular cancer who were treated with cisplatin-based chemotherapy had more severe side effects, including neurological side effects and Raynaud-like phenomena, than men who were not treated with chemotherapy, according to a new study published online November 25 in the Journal of the National Cancer Institute.Marianne Brydøy, M.D., of the Department of Oncology, Haukeland University Hospital, in Bergen, Norway, and colleagues conducted a cross-sectional study to...

As part of an ongoing consumer education and hearing health awareness campaign, which includes informational videos, an "Ask An Expert" forum, and the recently released "Hearing And Balance Report," AuDNet, Inc. has created a tip sheet for consumers that reveals certain over the counter and prescription drugs that may generate temporary and permanent hearing loss or deafness. "Over 100 prescription and over-the-counter drugs are known to cause hearing loss," remarked Robert M. DiSogra, Au.D....

Sound Pharmaceuticals has received the FDA notification that it may proceed with its Phase II study to prevent chemotherapy induced hearing loss. The Phase II study will enroll 80 patients with advanced head and neck, and non-small cell lung cancer at the National Center for Rehabilitative Auditory Research at the Veterans Administration Hospital and the Oregon Health and Science University in Portland, Oregon. One of the goals of this Phase II study is to reduce the incidence and severity...

SEATTLE, Aug. 7 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has received FDA notification that it may proceed with its Phase II study to prevent chemotherapy induced hearing loss. The Ph-II study will enroll 80 patients with advanced head and neck, and non-small cell lung cancer at the National Center for Rehabilitative Auditory Research at the Veterans Administration Hospital and the Oregon Health and Science University in Portland, Oregon. Hearing loss due to ototoxic medications such as...

Sound Pharmaceuticals has filed an investigational new drug application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebselen, SPI-3005, will be tested in advanced stage lung cancer and head and neck cancer patients receiving platinum based chemotherapy. This marks the second development program for SPI to enter clinical testing for a hearing loss indication....